NYSE:MANE Veradermics Q2 2026 Earnings Results & Report $115.96 -6.45 (-5.27%) Closing price 10/13/2026 03:59 PM EasternExtended Trading$117.24 +1.28 (+1.10%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Veradermics met analyst earnings expectations in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.58 versus the -$0.58 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 11, 2026TimeBefore Market OpensConference Call8:00 AM ET Veradermics EPS ResultsActual EPS-$0.58Consensus EPS -$0.58Beat/MissMet ExpectationsOne Year Ago EPSN/AVeradermics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Veradermics Q2 2026 Earnings FAQ Did Veradermics beat earnings estimates for Q2 2026? Veradermics (NYSE:MANE) reported earnings of -$0.58 per share for Q2 2026, matching the consensus estimate of -$0.58. The report was announced on Tuesday, August 11, 2026. Veradermics Earnings HeadlinesVeradermics: The Momentum Is Building, But Know This Before H2 2026 ReadoutsOctober 9, 2026 | seekingalpha.comVeradermics: Buy Before The CatalystsSeptember 18, 2026 | seekingalpha.comMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.October 14 at 1:00 AM | Crypto 101 Media (Ad)Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks TranscriptSeptember 9, 2026 | seekingalpha.comVeradermics to Present at Upcoming September Investor ConferencesSeptember 3, 2026 | businesswire.comCiti Sticks to Its Buy Rating for Veradermics, Incorporated (MANE)August 14, 2026 | theglobeandmail.comSee More Veradermics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Veradermics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veradermics and other key companies, straight to your email. Email Address About VeradermicsVeradermics (NYSE:MANE), Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for dermatologic diseases. The company’s research and development efforts are aimed at addressing conditions that affect the skin, hair and nails, with an emphasis on treatments designed to improve patient outcomes and quality of life. Veradermics is advancing a pipeline of investigational dermatology products across multiple disease areas. Its activities include the discovery, clinical development and potential commercialization of prescription therapies for conditions with unmet medical needs. As a development-stage company, its products remain subject to clinical testing and regulatory review before they can be broadly marketed. The company is headquartered in the United States and serves the dermatology market through its pharmaceutical development programs. Additional details about its commercial product portfolio, international operations and leadership are limited based on publicly available information.View Veradermics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
